Our research focusses on investigating the role of anti-tumour immunity (Type I Interferon activation in the tumour microenvironment) in therapeutic response. Using ovarian and bladder cancer patient derived specimens, cell lines and immunocompetent mouse models to study the tumour-immune interactions, the primary goals of our research program are,
- To define the role of sexual dimorphism and aging in anti-tumour immunity and treatment outcomes.
- To delineate the role of cancer cell intrinsic genetic events, such as DNA damage repair deficiency, in the evolution of distinct immune microenvironment landscapes.
- To develop combination immune priming approaches to enhance sensitivity to chemotherapy and immune checkpoint blockade therapy.
- To develop improved non-invasive immune monitoring approaches and biomarkers for application as prognostic and predictive indicators for personalized treatment of cancer.
Dr. Koti is a Veterinarian with PhD in Immunology. She is currently an Assistant Professor in the Departments of Biomedical and Molecular Sciences and Obstetrics and Gynaecology at Queen’s University. She is also cross-appointed to the Department of Urology and is a member of the Division of Cancer Biology and Genetics at QCRI.
RESEARCH FUNDED BY